For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Annexon, Inc.

USPTO Granted Patents = 14

EPO Patents = 5

Forward Citations = 31

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Arnon Rosenthal (9 out of 121 patents)

Michael W Leviten (9 out of 11 patents)

Sethu Sankaranarayanan (4 out of 4 patents)

4. Ted A Yednock (4 out of 11 patents)

5. Federico Sorana (3 out of 8 patents)

6. Dean R Artis (3 out of 40 patents)

7. Bruno Di Guglielmo (3 out of 3 patents)

8. Claudia Beato (3 out of 3 patents)

9. Luca B Mileo (3 out of 3 patents)

10. Colin P Leslie (3 out of 3 patents)

11. Chiara Padroni (3 out of 3 patents)

12. Federica Faroldi (1 out of 1 patent)

13. Alan S Verkman (38 patents)

14. Karen Krukowski (2 patents)

15. Susanna Rosi (0 patent)

14 patents: Sort by Forward Citations

1. 12735473 - METHOD OF TREATING A BLOOD DISORDER ASSOCIATED WITH C1Q-MEDIATED ACTIVATION OF THE CLASSICAL COMPLEMENT PATHWAY BY ADMINISTERING AN ANTI-C1Q ANTIBODY (2026-09-15),

2. 12534522 - ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF (2026-01-27),

3. 12522619 - Inhibitors of complement factors and uses thereof (2026-01-13),

4. 12509474 - Inhibitors of complement factors and uses thereof (2025-12-30),

5. 12486322 - ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES WITH SINGLE BINDING ARMS AND USES THEREOF (2025-12-02),

6. 11999779 - Anti-complement factor C1q Fab fragments and uses thereof (2024-06-04),

7. 11814404 - Inhibitors of complement factors and uses thereof (2023-11-14),

8. 11649279 - Anti-complement factor C1Q antibodies and uses thereof (2023-05-16),

9. 10927167 - Anti-complement factor C1Q antibodies and uses thereof (2021-02-23),

10. 10723788 - Anti-complement factor C1q Fab fragments and uses thereof (2020-07-28),

11. 10590190 - Anti-complement factor C1q antibodies and uses thereof (2020-03-17),

12. 10316081 - Humanized anti-complement factor C1Q antibodies (2019-06-11),

13. 10227398 - Anti-complement factor C1q antibodies and uses thereof (2019-03-12),

14. 9708394 - Anti-complement factor C1q antibodies and uses thereof (2017-07-18),

Annexon is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. The company is leveraging its proprietary anti-C1q antibody platform to address unmet medical needs in a broad spectrum of autoimmune and neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

14 Patents

#81 in South San Francisco, CA

#5,313 in California

#22,289 in US

#42,168 in the World

South San Francisco, CA, United States of America

Annexon, Inc.

Forward Citations = 31

13 inventors:

Arnon Rosenthal (9 out of 121 patents)

Michael W Leviten (9 out of 11 patents)

Sethu Sankaranarayanan (4 out of 4 patents)

4. Ted A Yednock (4 out of 11 patents)

5. Federico Sorana (3 out of 8 patents)

Please report any incorrect information to [email protected]

Loading…